250
Participants
Start Date
October 18, 2023
Primary Completion Date
June 24, 2025
Study Completion Date
October 28, 2025
Telmisartan/Amlodipine/Chlorthalidone 40/5/12.5 mg
PO, Once daily(QD), 8 weeks and 26 weeks if applicable
Telmisartan/Amlodipine/Hydrochlorothiazide 40/5/25 mg
PO, Once daily(QD), 8 weeks and 26 weeks if applicable
RECRUITING
The Catholic University of Korea, Uijeongbu ST. Mary's Hospital, Seoul
RECRUITING
Seoul national University Budang hospital, Seoul
RECRUITING
The Catholic University of Korea Bucheon St.Mary's Hospital, Seoul
RECRUITING
The Catholic University of Korea, ST. Vincent's Hospital, Gyeonggi-do
RECRUITING
he Catholic University of Korea, Incheon ST. Mary's Hospital, Incheon
NOT_YET_RECRUITING
Wonju Severance Christian Hospital, Gangwon-do
RECRUITING
The Catholic University of Korea Daejeon ST. Mary's Hospital, Daejeon
RECRUITING
Pusan National University Yangsan Hospital, Busan
RECRUITING
Chonnam National University Hospital, Gwangju
RECRUITING
Gwangju Veterans Hospital, Gwangju
RECRUITING
The Catholic University of Korea, Eunpyeong St. Mary's Hospital, Seoul
NOT_YET_RECRUITING
Hanyang university medical center, Seoul
RECRUITING
The Catholic University of Korea, Seoul ST. Mary's Hospital, Seoul
RECRUITING
The Catholic University of Korea, Yeouido ST. Mary's Hospital, Seoul
RECRUITING
Korea University Guro Hospital, Seoul
Yuhan Corporation
INDUSTRY